The abstract discusses a new approach to treating
relapsed/refractory multiple myeloma using a specific type of engineered immune cells. The focus is on a product called
ALLO-715, which is an allogeneic CAR T cell therapy targeting the B-Cell Maturation Antigen (BCMA). The therapy is advantageous due to its off-the-shelf availability and the ability to overcome logistical and manufacturing challenges associated with autologous CAR T cell treatments.
The ALLO-715 CAR T cells are created through a process that involves the use of a high-affinity single chain variable fragment (scFv) derived from a fully-human antibody, which is then incorporated into a second-generation CAR construct. This construct includes a safety feature that allows for the controlled elimination of the cells if necessary. The T cells are further modified to reduce the risk of
graft-versus-host disease and to provide resistance to a lymphodepleting agent.
In vitro studies have shown that ALLO-715 CAR T cells have a strong cytotoxic effect on target cell lines expressing
BCMA, but not on BCMA-negative cells. The cells also exhibit robust expansion and maintain a memory T cell phenotype. Long-term killing assays indicate that ALLO-715 CAR T cells can proliferate extensively and retain their cytolytic activity over an extended period.
The potency of ALLO-715 CAR T cells is not hindered by high levels of soluble BCMA, which can affect other BCMA-specific CARs. In mouse models with
multiple myeloma, ALLO-715 CAR T cells have shown high efficacy at a single dose. The administration of adeno-associated viruses to express human
IL-7 and
IL-15 has further enhanced the expansion and antitumor activity of the CAR T cells.
Tissue cross-reactivity studies using a fusion protein have confirmed the specificity of ALLO-715 for BCMA-expressing cells, with no significant off-target effects observed in other tissues. The manufacturing process for the CAR T cells has been shown to maintain cell viability, phenotype, and in vivo efficacy.
Overall, the findings suggest that ALLO-715 has the potential to be an effective allogeneic BCMA CAR T therapy for treating relapsed/refractory multiple myeloma and other
BCMA-positive cancers.
How to Use Synapse Database to Search and Analyze Translational Medicine Data?
The transational medicine section of the Synapse database supports searches based on fields such as drug, target, and indication, covering the T0-T3 stages of translation. Additionally, it offers a historical conference search function as well as filtering options, view modes, translation services, and highlights summaries, providing you with a unique search experience.

Taking obesity as an example, select "obesity" under the indication category and click search to enter the Translational Medicine results list page. By clicking on the title, you can directly navigate to the original page.

By clicking the analysis button, you can observe that GLP-1R treatment for obesity has gained significant attention over the past three years, with preclinical research still ongoing in 2023. Additionally, there are emerging potential targets, such as GDF15, among others.

Click on the image below to go directly to the Translational Medicine search interface.
